Tvardi Therapeutics, Inc.
TVRD
$3.02
$0.020.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 96.03% | 200.68% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.84% | 36.39% | -- | -- | -- |
| Operating Income | 4.84% | -36.39% | -- | -- | -- |
| Income Before Tax | 38.04% | -12.38% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 38.04% | -12.38% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.04% | -12.38% | -- | -- | -- |
| EBIT | 4.84% | -36.39% | -- | -- | -- |
| EBITDA | 4.85% | -36.55% | -- | -- | -- |
| EPS Basic | 77.44% | -5.27% | -- | -- | -- |
| Normalized Basic EPS | 77.44% | -5.27% | -- | -- | -- |
| EPS Diluted | 62.99% | -29.72% | -- | -- | -- |
| Normalized Diluted EPS | 77.32% | -5.48% | -- | -- | -- |
| Average Basic Shares Outstanding | 136.61% | 48.42% | -- | -- | -- |
| Average Diluted Shares Outstanding | 138.09% | 49.58% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |